Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study.
about
Targeted drugs in small-cell lung cancerTargeting angiogenesis in small cell lung cancerOvercoming chemoresistance of small-cell lung cancer through stepwise HER2-targeted antibody-dependent cell-mediated cytotoxicity and VEGF-targeted antiangiogenesis.Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance).Meta-analysis of the role of bevacizumab in extensive stage small cell lung cancer.Treatment options for small cell lung cancer - do we have more choice?Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumorsChemotherapy for small cell lung cancer: a comprehensive reviewSmall cell lung cancer: will recent progress lead to improved outcomes?A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.Efficacy and safety of angiogenesis inhibitors in small-cell lung cancerLung cancer: Biology and treatment options.Targeted therapies in small cell lung cancerSmall Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?The development of targeted therapy in small cell lung cancer.Research progress in the treatment of small cell lung cancer.Emerging drugs for small cell lung cancer--an update.Management of malignant pleural effusion by suicide gene therapy in advanced stage lung cancer: a case series and literature review.Medical treatment of small cell lung cancer: state of the art and new development.Anti-angiogenesis in Personalized Therapy of Lung Cancer.Progress and challenges in the treatment of small cell lung cancer.Phase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer.Treatment update in small-cell lung cancer: from limited to extensive disease.Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer.Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models.A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113.Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†.Advanced small cell lung cancer (SCLC): new challenges and new expectations.Trial watch: Monoclonal antibodies in cancer therapy
P2860
Q26767017-F0D04D7A-DB81-4CEF-9CB6-BE670D4614BBQ28068385-FA35BC19-9C26-4C82-BEDA-13B23DA3613FQ30544833-2967026B-0178-4427-90F1-B80C1BA20A9FQ33420821-1AFDE76A-FD30-43B9-A6F6-32D41CA52A72Q33443519-E1659D9A-626A-4569-B641-49CBF3F17269Q33723735-67434F2C-C4D4-43A8-BC05-2F4678385B28Q35051964-5E1787F3-A265-41F3-816F-B3EAB11F450FQ35569379-EC072E56-9444-49FD-98B8-63D1BBA5E13DQ35836257-79E36546-CA96-403C-B2C6-EFAC7AF91229Q36163040-F6218D92-5499-4BEA-975B-79F513E35C9CQ36207730-EB420C9C-38E1-4AE0-A825-9032DA864024Q36328370-0E915FD5-C554-4332-9591-2E0ED5A10A23Q36475811-30621D6B-2B60-4C4D-9E22-19CBF79BF5EFQ36811784-66083E8D-87F9-4FC4-A887-B55F5B6373CAQ37127932-B4BCD9FE-E8AC-4C74-81EA-4EE4EB1E5036Q37604301-030AEE52-FE77-4094-82CB-6E28A9CB6425Q37979856-8FB3F83B-C14B-4ED6-84EB-849E00FE5C16Q38022486-10BAB819-F110-4F2D-A394-A80C0350717DQ38125489-58581444-C157-4FB3-9C06-ECC6593AF754Q38669276-1A0DACC9-DD6A-4547-8E25-9AE6EB4A70C3Q39272825-4AA0DE94-F571-4B19-B179-499AFFFA86ADQ40901357-42E8BD76-B6E0-457C-B50E-33DAEE7E6B67Q43939698-5550C505-7D3D-4CFC-AB0B-BBD84E85080BQ45304925-5B94F343-DB81-42C8-AF25-E198AC9A340DQ46659724-74F43BC4-9B26-48C9-9D9B-223E19B0C718Q48374393-87D854B9-B737-4A4E-8DBA-C7603C8DB14DQ51658011-E4B01B64-7013-49E1-8543-843E2466CA8DQ54977232-60A50A1D-028B-4F1D-A3CF-A4D6FFC5BE95Q56932681-2BA7C915-D047-47B4-88A9-205BB03E6818
P2860
Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study.
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Cisplatin, irinotecan, and bev ...... CALGB 30306, a phase II study.
@ast
Cisplatin, irinotecan, and bev ...... CALGB 30306, a phase II study.
@en
type
label
Cisplatin, irinotecan, and bev ...... CALGB 30306, a phase II study.
@ast
Cisplatin, irinotecan, and bev ...... CALGB 30306, a phase II study.
@en
prefLabel
Cisplatin, irinotecan, and bev ...... CALGB 30306, a phase II study.
@ast
Cisplatin, irinotecan, and bev ...... CALGB 30306, a phase II study.
@en
P2093
P2860
P356
P1476
Cisplatin, irinotecan, and bev ...... CALGB 30306, a phase II study.
@en
P2093
Arkadiusz Z Dudek
Herbert H Pang
Lydia D Hodgson
Mark R Green
Neal E Ready
Stephen L Graziano
P2860
P304
P356
10.1200/JCO.2011.35.6923
P407
P577
2011-10-03T00:00:00Z